Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease

Świderska, Magdalena; Jaroszewicz, Jerzy; Parfieniuk‐Kowerda, Anna; Rogalska, Magdalena; Stawicka, Agnieszka; Panasiuk, Andrzej; Flisiak, Robert

doi:10.1155/2017/3480234

Cited by 13 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 Swiderska M and his colleges found altered levels of CK18 depending upon the severity of disease inspite of having normal serum ALT. 10 Incontrast to this, our study found positive association of CK18 with serum ALT. Study conducted by Alt Y and his colleagues are in agreement to our results concerning serum ALT as they reported similar association.…”

Section: Discussionsupporting

confidence: 75%

Association of liver biomarkers and cytokeratin-18 in Nonalcoholic fatty liver disease patients

et al. 2020

View full text Add to dashboard Cite

Objective: To investigate the association of gold standard liver biomarkers with serum cytokeratin 18 (CK18), serum Alanine aminotransferase (ALT) and serum aspartate (AST). Methods: This was cross sectional study. It was conducted at Mayo Hospital from January 2016 to December 2017. It comprised of 148 non-alcoholic fatty liver disease subjects of age 40-60 years. After written informed consent, study anthropometric measurements (age, height, waist circumference and hip circumference) were taken and serum AST, ALT and CK-18 were estimated by sandwiched ELISA technique. Data was analyzed using SPSS 21.0. Descriptive were presented as mean and standard deviation. Association between CK18, serum AST and ALT were analyzed by regression analysis and are presented as beta coefficient. P-value ≤ 0.05 was taken as significant. Results: Study comprised of 148 subjects with mean age 44.81±6.2. Of total population 29.1% were male and 70.9% were female. Significant positive association of CK18 was found with serum ALT (P-value 0.005*). However, no association was found between AST and serum CK18. (P-value 0.29). Conclusion: Significant positive association was found between Serum CK18 and serum ALT. doi: https://doi.org/10.12669/pjms.36.3.1674 How to cite this:Altaf B, Rehman A, Jawed S, Raouf A. Association of liver biomarkers and cytokeratin-18 in Nonalcoholic fatty liver disease patients. Pak J Med Sci. 2020;36(3):---------. doi: https://doi.org/10.12669/pjms.36.3.1674 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionsupporting

confidence: 75%

Association of liver biomarkers and cytokeratin-18 in Nonalcoholic fatty liver disease patients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A high proportion of upper tertile of cK18 and K18 was observed throughout the entire hospitalization.4 | D ISCUSS I ONKnowledge of hepatocyte death in the background of HBV infection is limited. Our previous study and others confirmed that hepatocyte cell death as evaluated with serum biomarkers, K18 (total cell death) and cK18 (apoptosis), is closely associated with hepatic inflammation and HBV DNA activity in relative stable stage without complications of cirrhosis 23,41,42. However, in the stage of decompensated cirrhosis with HBV infection, the varied HBV DNA activity, hepatic insufficiency, portal hypertension, altered immunopathology and hepatic and extra-hepatic organ dysfunction/failure make the profile of hepatocyte death rather intricate.…”

supporting

confidence: 56%

Serum keratin‐18 fragments as cell death biomarker in association with disease progression and prognosis in hepatitis B virus‐related cirrhosis

Chen

Liu

et al. 2019

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Extensive hepatocyte death leads to hepatic inflammation and contributes to systemic inflammation in decompensated cirrhosis. We aimed to investigate the prognostic value of serum cell death markers in patients with hepatitis B virus (HBV)‐related acute decompensation (AD) of cirrhosis with and without acute‐on‐chronic liver failure (ACLF). We studied two cohorts—cohort 1: 201 outpatients with stable chronic hepatitis B (49 cirrhosis); cohort 2: 232 inpatients with HBV‐related cirrhosis admitted for AD. Cell death was determined with serum keratin‐18 (K18) for total death and serum caspase‐cleaved‐K18 (cK18) for apoptosis. Survival analyses were performed using competing risk method. We found that serum K18 and cK18 were significantly (P < 0.001) higher in patients from cohort 2 than those from cohort 1. Among cohort 2, ACLF patients had significantly (P < 0.001) increased K18 and cK18 comparing to those without ACLF. Increased K18 and cK18 were mainly attributed to HBV flare and were associated with liver and coagulation failure. HBV‐AD patients without ACLF who admitted with upper tertile of K18 or cK18 were at higher risk of developing ACLF during follow‐up. Baseline serum K18 or cK18 was significantly associated with transplant‐free 90‐day survival independent of leucocytes, HBV DNA, bacterial infection, encephalopathy and severity scores. The combination of cell death biomarkers significantly improved the prognostic value of the currently established prognostic scores. The reduction of cell death level after standard treatment was associated with increased short‐term survival. In conclusion, measurements of serum K18 or cK18 in HBV decompensated cirrhosis are a promising tool for predicting ACLF and risk stratification of short‐term outcome.

show abstract

“…Increased levels of M30 as a marker of apoptosis predicted non-hepatocellular carcinoma liver-related mortality in patients with alcoholic cirrhosis [ 20 ]. The predictive and prognostic value of M30 in patients with different liver diseases was studied previously [ 43 – 47 ]. We investigated the predictive value of pre-transplant M30 and M65 levels in cirrhotic patients with different original diseases.…”

Section: Discussionmentioning

confidence: 99%

Serum Caspase-Cleaved Cytokeratin (M30) Indicates Severity of Liver Dysfunction and Predicts Liver Outcome

Oweira¹,

Sadeghi

Daniel

et al. 2018

Ann Transplant

View full text Add to dashboard Cite

BackgroundThe Model for End-Stage Liver Disease (MELD) score is a well-established tool for assessing hepatic failure. The present retrospective study investigated whether serum keratin 18 (M65) and caspase-cleaved cytokeratin (M30) were associated with liver dysfunction and post-transplant graft failure.Material/MethodsA total of 147 patients with liver cirrhosis were categorized into 2 groups according to their baseline MELD score (group I: MELD score <20, n=87, and group II: MELD score ≥20, n=60). Serum M65 and M30 levels were measured by ELISA.ResultsCirrhotic patients had significantly higher serum M65 and M30 levels than healthy controls (p<0.0001). Serum M65 was correlated with the MELD score and serum bilirubin (p≤0.007) and serum M30 was correlated with the MELD score, international normalized ratio, and serum bilirubin (p≤0.001). Group II had significantly higher serum M65 and M30 levels than group I (M65, p=0.025 and M30, p<0.001). Patients who lost the allograft during the first post-transplant year had significantly higher serum M30 levels than patients with a graft survival of >1 year (p=0.004). In the regression analysis, serum M30 was associated with the MELD score (odds ratio [OR]=2.545, p=0.005), serum bilirubin (OR=2.605, p=0.005) and 1-year graft loss (OR=3.61, p=0.006).ConclusionsOur data indicate that serum M30 levels reflect the degree of liver dysfunction and can predict 1-year graft loss.

show abstract

Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease

Cited by 13 publications

References 38 publications

Association of liver biomarkers and cytokeratin-18 in Nonalcoholic fatty liver disease patients

Association of liver biomarkers and cytokeratin-18 in Nonalcoholic fatty liver disease patients

Serum keratin‐18 fragments as cell death biomarker in association with disease progression and prognosis in hepatitis B virus‐related cirrhosis

Serum Caspase-Cleaved Cytokeratin (M30) Indicates Severity of Liver Dysfunction and Predicts Liver Outcome

Contact Info

Product

Resources

About